MK-1167 (via Merck)
Cognitive Dysfunction (Alzheimer's, Schizophrenia)
Phase 2 (imminent)Partnered
Key Facts
Indication
Cognitive Dysfunction (Alzheimer's, Schizophrenia)
Phase
Phase 2 (imminent)
Status
Partnered
Company
About Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.
View full company profile